Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

DARZALEX 20 mg/mL concentrate for solution for infusion

Active Ingredient:
daratumumab
Company:  
Janssen-Cilag Ltd (a Johnson & Johnson Company) See contact details
ATC code: 
L01FC01
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

HCPs-_Important information on safety and risk minimisation of Daratumumab and interference with Blood Compatability Testing

{healthcare_pro_orange} For Healthcare Professionals

Inform health care professionals of the interference of Darzalex (daratumumab) with antibody screening and crossmatching

{pdf_link}

Important Information about Blood Transfusions

Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.

{pdf_link}

Important information on safety and risk minimisation of Daratumumab and Interference with Blood Compatibility Testing

{healthcare_pro_orange} For Healthcare Professionals

Information for Blood Banks on the intereference with Antiglobulin Test _blood typing

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Janssen-Cilag Ltd (a Johnson & Johnson Company)
Company image
Address
50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone
+44 (0)1494 567 567
Medical Information Fax
+44 (0) 1494 567 445
WWW
https://innovativemedicine.jnj.com/uk/
Fax
+44 (0)1494 567 568
Medical Information Direct Line
+44 (0)800 731 8450
Customer Care direct line
+44 (0)800 731 5550
Medical Information e-mail
[email protected]